Phase 1 Oesophageal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed (through a tissue or cell sample) with one of the following advanced or metastatic cancers: non-small cell lung cancer (squamous or adenocarcinoma type), triple-negative breast cancer, head and neck squamous cell cancer, esophageal squamous cell cancer, esophageal adenocarcinoma, stomach or gastroesophageal junction adenocarcinoma, cervical cancer, endometrial cancer, or ovarian cancer.
- People whose general health and ability to carry out daily activities is rated as fully active or restricted only in physically strenuous activity (this is measured on a standard scale used by doctors, called ECOG 0 or 1).
- People whose liver, kidneys, lungs, and heart are functioning at an adequate level, as determined by the trial site.
- People whose blood cell counts and related measures are at adequate levels, as determined by the trial site.
Who may not be able to join:
- People who have received certain cancer treatments — including chemotherapy, biological therapies, checkpoint inhibitor drugs, or radiation therapy (other than radiation to bone only) — within approximately 3 weeks or 5 half-lives of the first trial dose, whichever is the shorter period.
- People with a history of moderate lung inflammation (pneumonitis) that required steroid treatment, or any severe or life-threatening lung inflammation from a previous treatment.
- People who have taken part in another clinical trial and received an investigational (experimental) treatment within approximately 4 weeks or 5 half-lives of the first trial dose, whichever is the shorter period.
- People who still have significant side effects from previous cancer treatment that have not resolved — with the exception of hair loss, or mild-to-moderate nerve-related symptoms (such as tingling or numbness).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Viviana Bozon, MD, Normunity AccelCo, Inc.
Phone: 215-593-7119
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of treatment-emergent adverse events (TEAE); Incidence of dose-limiting toxicities (DLTs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.